News
-
-
PRESS RELEASE
Promatix Biosciences Highlights the Power of its Logic-Gated Proteomics-Driven Bispecific Discovery Platform to Expand the Tumour-Selective Target Space for Next-Generation ADCs at AACR 2026
Promatix Biosciences showcases its Logic-Gated Proteomics-Driven Bispecific Discovery Platform expanding target space for Next-Generation ADCs at AACR 2026 -
-
PRESS RELEASE
Promatix Biosciences Presents Positive Preclinical Data with First-in-Class PBS293 EGFR×EphA2 Cis-Bispecific ADC Demonstrating Enhanced Tumour Selectivity
Promatix Biosciences presents positive preclinical data at the 16th World ADC London Summit on PBS293-MMAE, a novel bispecific ADC for colorectal cancer, demonstrating enhanced tumour selectivity and efficacy
